Dapoxetine Research Overview
Dapoxetine 60mg (Poxet by Sunrise) is a selective serotonin reuptake inhibitor (SSRI) developed for research into neurochemical pathways and serotonin transporter mechanisms. This pharmaceutical-grade compound enables precise laboratory investigation of serotonergic modulation in controlled experimental settings. Researchers examining neurotransmitter dynamics and receptor pharmacology find dapoxetine valuable for its rapid onset and short half-life characteristics. Our Stroid UK Shop maintains pharmaceutical standards for all neurochemical modulators, ensuring consistent quality for academic institutions and licensed laboratories.
Laboratory Applications
Dapoxetine demonstrates selective inhibition of the serotonin transporter (SERT) without significant effects on dopamine or norepinephrine reuptake systems. Researchers studying serotonergic pathways analyse its rapid pharmacokinetic profile, with peak plasma concentrations achieved within 1-2 hours post-administration in animal models. The compound’s short elimination half-life of approximately 1.5 hours makes it suitable for acute experimental protocols. Studies examining neural plasticity, synaptic transmission, and behavioural neuroscience utilise dapoxetine to investigate serotonin-dependent mechanisms. Comparative research with other selective modulators helps elucidate differential receptor binding profiles and downstream signalling cascades.
Research Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Dapoxetine HCl |
| Concentration | 60mg per tablet |
| CAS Number | 129938-20-1 |
| Molecular Formula | C₂₁H₂₃NO·HCl |
| Molecular Weight | 341.87 g/mol |
| Manufacturer | Sunrise Pharmaceuticals |
| Storage | Room temperature, dry conditions |
| Purity | Pharmaceutical grade |
Laboratory protocols should account for dapoxetine’s selective pharmacological profile when designing experimental frameworks. Research facilities investigating serotonin transporter kinetics benefit from this compound’s well-characterised binding affinity and selectivity ratios. Cross-referencing studies with receptor modulators and signalling peptides provides comprehensive insights into neurochemical interactions and therapeutic target identification.
Research Compliance
This dapoxetine preparation is intended exclusively for qualified research applications and in-vitro laboratory studies. Not approved for human consumption, therapeutic use, or clinical administration. Researchers must comply with institutional guidelines and maintain appropriate safety protocols when handling neurochemical compounds. All studies should be conducted under proper laboratory supervision with adequate ventilation and safety equipment.
